AMPA receptor

GYKI-47261 is a selective, competitive antagonist of the AMPA receptor, exhibiting an IC50 of 2.5 μM. This compound demonstrates significant anticonvulsive activity and provides neuroprotective effects, making it valuable in neurological research. Additionally, GYKI-47261 is a potent inducer of CYP2E1, highlighting its potential implications in drug metabolism studies.

(R)-3,4-DCPG is a selective antagonist of AMPA and NMDA receptors, demonstrating a Kd of 77 μM for AMPA. At a concentration of 500 μM, it fully antagonizes NMDA-induced depolarization, while exhibiting weaker antagonistic effects on kainate-induced depolarizations. This compound is valuable for research exploring synaptic transmission and neuropharmacology, particularly in studies investigating excitotoxicity and related neurological disorders.

AMPA Receptor Modulator-4 is an orally active positive allosteric modulator targeting AMPA receptors (AMPAR PAM). This compound, a 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide, effectively crosses the blood-brain barrier. Research indicates that AMPA Receptor Modulator-4 enhances cognitive function and improves working memory performance in murine models, making it a valuable tool for studies on cognitive enhancement and neurological disorders.

JAMI1001A is a positive allosteric modulator of the AMPA receptor, which plays a crucial role in synaptic transmission and plasticity. This compound effectively enhances receptor activation by modulating the deactivation and desensitization processes of both flip and flop isoforms. JAMI1001A is primarily utilized in neurological research to investigate synaptic function and potential therapeutic strategies for cognitive disorders.

PF-04701475 is a potent AMPA receptor potentiator with an EC50 of 123 nM. This compound enhances synaptic transmission mediated by AMPA receptors, making it valuable for investigating mechanisms underlying neurological disorders. PF-04701475 can aid in the exploration of potential therapeutic strategies for conditions such as depression and cognitive decline.

DL-Willardiine is an AMPA receptor antagonist with an IC50 of 2 μM. It is employed in neuropharmacology research to investigate excitatory neurotransmission and its implications in various neurological disorders. This compound serves as a valuable tool in studying the mechanisms of synaptic transmission and the effects of glutamatergic signaling.

Philanthotoxin 74 diTFA is a selective AMPA receptor antagonist, primarily targeting the GluR3 and GluR1 subunits with IC50 values of 263 nM and 296 nM, respectively. This compound is instrumental in studies focused on synaptic transmission and neuropharmacology, providing valuable insights into excitatory neurotransmission and potential therapeutic interventions for neurological disorders. Its specificity makes it a useful tool for researchers investigating the role of AMPA receptors in various biological contexts.

UoS12258 is a selective positive allosteric modulator of the AMPA receptor, enhancing AMPA receptor-mediated synaptic transmission. This compound demonstrates significant potential in improving cognitive performance in various rat models, particularly in scenarios involving scopolamine-induced impairment and water maze tasks in aged rats. UoS12258 serves as a valuable tool for research in cognitive enhancement and synaptic function.

LY-503430 is an orally active positive allosteric modulator of the AMPA receptor. This compound enhances AMPA receptor activity, making it useful for investigating synaptic transmission and neuronal excitability. LY-503430 is particularly relevant in research focused on neurological disorders, including Parkinson's disease.